Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program.
Javier Arranz-NicolásMiguel Martin-SalgadoIrene Adán-BarrientosRosa LiébanaMaría Del Carmen Moreno-OrtízJudith LeitnerPeter SteinbergerAntonia Ávila-FloresIsabel MeridaPublished in: Cancer immunology, immunotherapy : CII (2021)
Our results indicate that DGKα inhibition could provide an important mechanism to revert exhausted T lymphocyte phenotypes and thus favor proper anti-tumor T cell responses. The cooperative effect observed after PD-1/PD-L1 and DGKα blockade offers a promising strategy to improve the efficacy of immunotherapy in the treatment of cancer.